GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex(R) in the Treatment of Lennox-Gastaut Syndrome

[GlobeNewswire] – LONDON — GW Pharmaceuticals plc (AIM:GWP) (GW) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Epidiolex(R), GW’s product candidate … more

View todays social media effects on GWPH

View the latest stocks trending across Twitter. Click to view dashboard

See who GW is hiring next, click here to view